Latest Breaking News On - Jan hoflack - Page 2 : comparemela.com

Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program

Oncodesign Precision Medicine Obtains Deep Tech Development Funding for Its ANIMUS Program
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Karine lignelMathilde bohin alban dufumierPhilippe genneJan hoflackArthur rouillTech development fundPrecision medicineDeep tech developmentAi boosted nanocyclixArtificial intelligenceMachine learningDeep learningDrug discoveryDeep tech development fundOncodesign precision medicineBourgogne franche comt

Oncodesign Precision Medicine: OPM Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers

Oncodesign Precision Medicine: OPM Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalKarine lignelArthur rouillMathilde bohin alban dufumierJan hoflackData review committeePrecision medicineChief scientific officerChief executive officerOncodesign precision medicineGeneral managerBohin alban dufumier

OPM Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers

OPM Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalJan hoflackArthur rouillMathilde bohin alban dufumierKarine lignelData review committeePrecision medicineChief scientific officerChief executive officerOncodesign precision medicineAlban dufumierOncodesign precision

OPM Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers

Completion of the single-dose administration (SDA) part of the Phase 1 healthy volunteers study of OPM-101 and transition to the multiple-dose escalation administration (MDA)A new mechanism of action normalizing TNF-alpha secretion and targeting chronic inflammatory bowel disease (IBD)Excellent tolerability with no.

France generalMathilde bohin alban dufumierJan hoflackArthur rouillKarine lignelData review committeeRegulatory newsPrecision medicineChief scientific officerChief executive officerOncodesign precision medicineAlban dufumier

OPM Announces Its 2022 Annual Results and Provides an Update on Its Clinical Developments

Revenues and operating income in 2022 of €8.3 M (+110% vs. 2021 proforma), including revenues of €8 M, mainly driven by a €7 M milestone and a €0.5 M up-frontNet income almost at break-even (€0.2) MStrong financial visibility with a cash position of €13.4 M ensuring the development of our programs for the coming yea.

Philippe genneArthur rouillKarine lignelJan hoflackMathilde bohin alban dufumierResearch tax creditTransition service agreementOncodesign servicesRegulatory newsPrecision medicineChief executive officerOncodesign biotechnologyEuronext growthArtificial intelligenceMonday aprilOrdinary general meeting